Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine + DLI for Relapsed AML/MDS Post-Transplant
NCT02684162Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2016
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2016; status: completed.
02
Drugs
guadecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02684162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684162.